Thyroid Eye Disease (TED) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Thyroid Eye Disease (TED) Emerging Therapy and TPP Insights

Thelansis’s “Thyroid Eye Disease (TED) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Thyroid Eye Disease (TED) Overview

Thyroid eye disease is an autoimmune condition, most often occurring alongside Graves’ disease, in which inflammation and tissue remodeling around the eyes cause swelling, bulging, double vision, and in more severe cases, vision-threatening complications. The underlying biology centers on overactivation of a growth factor receptor pathway on cells behind the eye, a mechanism that remained poorly understood for a long time, leaving management largely reactive, built around corticosteroids to control acute inflammation, radiation in select cases, and surgery once the disease had stabilized to correct residual bulging or double vision rather than prevent it. That changed with the approval of the first medicine specifically designed to block this growth factor pathway directly, a genuine breakthrough that reduced eye bulging and inflammatory activity in trials and has since shown continued benefit in real-world use, including among patients who had already failed steroids, radiation, or surgery. The treatment class continues to expand globally, and head-to-head comparisons against traditional steroid therapy are now underway.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)